SOURCE: BioMedReports


June 16, 2010 09:02 ET

Report: Several Parties Interested in Northwest Biotherapeutics' Immunotherapy Cancer Vaccines

LOS ANGELES, CA--(Marketwire - June 16, 2010) -  Last week, a detailed report authored by renowned research pharma analyst Dr. Navid Malik caused some excitement in the pharmaceutical industry about Northwest Biotherapeutics' (OTCBB: NWBO) DCVax® immunotherapy vaccines to treat cancer.

In an interview with BioMedReports, Northwest's Chairperson Linda Powers says:

"I can tell you that the company has received multiple inquiries about DCVax® prostate, not surprisingly in the post-Dendreon period, from big pharma as well as financial parties, and we think it will be a huge newsworthy event when we do that transaction. We've begun focusing on that and we're allowing ourselves some time to get the right transaction done. That, I think, will be a major milestone kicking off, especially if we go the route of a partnering deal. Obviously, that would be a major announcement and event.

The news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence has the complete interview at BioMedReports.Com.

Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:

About BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies.

For more biomedical sector and investment news go to

Contact Information

  • Media Contacts Only:
    Mary Davila
    Assistant Editor
    e-mail: Email Contact
    Tel: +1 323 472 4480
    Fax: +1 888 210 3556